ADC Therapeutics to Hold Q2 2024 Financial Results Call on August 6

ADC Therapeutics SA, a leading company in the field of antibody drug conjugates (ADCs) based in Lausanne, Switzerland, will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT. This event will focus on disclosing the company's financial performance for the second quarter of 2024 and providing updates on its operations.

ADC Therapeutics, a commercial-stage pioneer in ADCs, is committed to revolutionizing treatment for patients suffering from hematologic malignancies and solid tumors. The company's proprietary ADC technology is at the forefront of this transformation. One of its key products, ZYNLONTA (loncastuximab tesirine-lpyl), targets CD19 and has received accelerated approval from the FDA and conditional approval from the European Commission. This approval is for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also being developed for use in combination with other treatments and in earlier lines of therapy.

Beyond ZYNLONTA, ADC Therapeutics has an extensive pipeline of ADCs in various stages of clinical and preclinical development. The company's commitment to innovation and advanced research is evident in its ongoing efforts to develop new treatments and improve existing ones.

ADC Therapeutics operates not only from its headquarters in Lausanne but also has significant operations in London and New Jersey. The company remains focused on expanding its global footprint and enhancing its capabilities to better serve patients worldwide.

For those interested in participating in the upcoming conference call, registration is required. Registrants will receive a dial-in number and a unique PIN. It is advised to join the call 10 minutes before the scheduled time, although pre-registration is possible at any time. Additionally, a live webcast of the call will be accessible in the “Events and Presentations” section of the Investors section on the ADC Therapeutics website. The webcast will be archived and available for 30 days following the call, offering flexibility for those unable to attend the live event.

ADC Therapeutics' focus on antibody drug conjugates distinguishes it as a leader in the biopharmaceutical industry. The company’s innovative approach aims to provide new therapeutic options for patients with challenging cancers, reflecting its dedication to improving patient outcomes and advancing medical science.

For more comprehensive information about ADC Therapeutics and its initiatives, individuals are encouraged to visit the company's website and follow its updates on LinkedIn. The company continues to drive forward with its mission to transform the treatment landscape for cancer patients globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!